AI applications & software · Industry Index 7 (rank #171) · $3.5B — Series C, 2025-11editorial estimate
ⓘ Data freshness
price: no data index: as of 2026-10-29 fundamentals: no data No structured SEC filings
Deep funding / news coverage runs mega-caps first — Hippocratic AI is in the graph, but detailed data isn't ingested yet.
Patient-facing generative AI agents for non-diagnostic clinical work, sold to health systems, payors and pharma. Reports 115M+ clinical patient interactions since commercialisation.
Industry exposure 1.0 (Pure-play AI application: patient-facing clinical agents are the product.)
Signal
signal: no data
Not scored (private). Hippocratic AI is a private company, so its directional signal is not published.
Relationship network
Loading relationship graph…
NVIDIA — portfolio company
Key relationships
NVIDIA — portfolio company · NVIDIA's venture arm NVentures participated in Hippocratic AI's $126M Series C at a $3.5B valuation. source: hippocraticai.com
Unusual options activity needs a US-listed instrument; this company has none.
Not scored (private)
We don’t publish a directional call for private companies.
No moat profile yet. The durable competitive advantage — moat, leadership, and pricing power — is curated for flagship names first; Hippocratic AI isn't covered yet. Nothing here is fabricated in its absence.
Signal contribution
The moat prior — a subjective, non-backtested editorial input — only nudges the long (~6-month) horizon, and it isn't scoring Hippocratic AI yet (directional scores are withheld for private companies). Nothing here is fabricated in its absence.
Owns the customer and performs the patient interaction itself at real volume, but three of five dimensions are undocumented in the cited source. Included at that grain deliberately: the rubric records what is evidenced, and a company can carry serious traction while most of the stack stays unestablished.
Contracts directly with 50+ large health systems, payors and pharma clients across six countries, including named providers such as Cleveland Clinic, Northwestern Medicine, Ochsner Health and Moffitt Cancer Center. source: hippocraticai.com
Looked for a proprietary corpus or an exclusive data right and found none described; 115 million clinical patient interactions are reported as a volume of work performed, which is not the same as a claimed data asset. Absence of evidence, not evidence of absence. source: hippocraticai.com
The announcement names a "Polaris Safety Constellation Architecture" it will keep investing in, but does not define it, describe its methodology, or establish it as an evaluation system Hippocratic owns — so the band cannot be raised on the strength of the name alone. source: hippocraticai.com
The patient interaction itself happens inside the product: 115 million clinical patient interactions completed in the 15 months since commercialisation, rather than the product handing a task back to staff to perform. source: hippocraticai.com
The announcement does not state whether the company trains its own models or builds on a third-party base. Looked for a model description in the cited source and found none. source: hippocraticai.com
Hippocratic AI's April 2026 Polaris 5.0 release says the model was built on more than 180 million real-world patient interactions and validated by over 7,500 U.S.-licensed clinicians. The AI is the product rather than a feature: voice agents run post-discharge, medication-adherence and screening outreach calls as standing workflow at Universal Health Services, WellSpan Health, Cincinnati Children's, University Hospitals and Sheba Medical Center, with customer case studies citing a 30% readmission reduction and an 89% connection rate. The agent catalogue exceeds 1,000 prebuilt agents. Headroom remains visible: University Hospitals describes initial pharmacy-related deployments ahead of wider rollout, and the life-sciences arm dates only to a January 2026 acquisition. source: hippocraticai.com
A paired axis, not a sixth band: it is never counted in the pattern above and the two are never averaged into one score.
funding: Series C led by Avenir Growth with CapitalG, General Catalyst, a16z, Kleiner Perkins, NVIDIA's NVentures and health-system investors; total raised $404M. ($126M at $3.5B valuation) 2025-11-03source: hippocraticai.com
usage: Clinical patient interactions completed in the 15 months since commercialisation, reported with no safety issues. (115M+ interactions) 2025-11-03source: hippocraticai.com
Scouted against the condition: a company that simultaneously owns the customer relationship, the data, the evals, the workflow, and a domain-specific model. Weightless — this profile never affects a signal, and it is not a forecast of returns.
No structured SEC filings. Hippocratic AI does not file XBRL with the SEC; see funding rounds under Investors.
Funding rounds
No recorded funding rounds.
Headline valuation: $3.5B — Series C, 2025-11 editorial estimate
